Public-domain · open source
OpenJurist
← 880 F.3d 304 - Guilbeau v. Pfizer Inc.

Guilbeau v. Pfizer Inc.’s Empirical Analysis

880 F.3d 304 · 2018

Citation profile

6
cited by 6 later decisions
1
states following
June 2023
most recently cited

2 federal appellate · 1 state decisions

Relationships

Applies 21 U.S.C. § 331 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 28 U.S.C. § 1407 · 5 U.S.C. § 552 (Freedom of Information Act)

Relies on Wyeth v. Levine · Watters v. Wachovia Bank, N. A. · Sorrell v. IMS Health Inc. · PLIVA, Inc. v. Mensing · PLIVA, Inc. v. Mensing

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 6 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “an actual conflict between state and federal law such that it is impossible for a person to obey both.”
    1 later decision quote this exact passage · from the majority
  2. “federal law controls and the state-law tort claims must be dismissed.”
    1 later decision quote this exact passage · from the majority
  3. “preemption is a legal question for determination by the courts....”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.